Alnylam Gains 2.36% on FDA Support and Buy Rating as Top 500 Volume Strategy Yields 31.52% Return

Alnylam Pharmaceuticals (NASDAQ:ALNY) rose 2.36% on August 14, 2025, with a trading volume of $0.55 billion, down 38.55% from the previous day’s volume. The stock’s performance was influenced by recent regulatory developments and analyst activity. An FDA advisory panel supported Alnylam’s vutrisiran for expanded use in treating rare heart disease, signaling potential market expansion. Despite this, the company faces scrutiny over its hypertension drug’s efficacy, with regulators questioning mid-stage trial results.

Analysts remain cautiously optimistic, with a “Moderate Buy” consensus rating and a $247.40 price target, implying a 44.2% upside from current levels. Institutional ownership remains strong at 93.98%, though insider selling has persisted, with $2.81 million in shares sold in the past quarter. Alnylam’s pipeline, including vutrisiran and zilebesiran for hypertension, highlights its focus on high-impact therapeutic areas. However, ongoing regulatory uncertainty and negative earnings—trailing P/E of -19.92—underscore risks for investors.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to now delivered moderate returns. The 1-day return was 0.98%, with a total return of 31.52% over 365 days. This indicates the strategy captured some short-term momentum but also reflected market volatility and potential timing risks.